Publicacións en colaboración con investigadores/as de Gustave Roussy Cancer Campus (2)

2021

  1. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study

    The Lancet Respiratory Medicine, Vol. 9, Núm. 6, pp. 613-621

2020

  1. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors

    Annals of Oncology, Vol. 31, Núm. 10, pp. 1405-1412